Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor
AssigneeImmunicon Corporation
InventorPaul A. Liberti
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmunicon Corporation
InventorPaul A. Liberti
Estimating the term…
A test system and procedure for quantitatively assaying biological material for a target immunological substance by means of immunochemical binding of immune complexes, comprising the target substance and its immunospecific conjugate, to insolubilized non-immunospecific factor, such as Clq. A sample of biological material suspected of containing the target substance is introduced into the test system including pre-determined amounts of the target substance and its immunospecific conjugate forming immune complexes having a known degree of chemical binding to the non-immunospecific factor. The amount of target substance present in the test sample is determined according to the deviation from the known degree of immunochemical binding caused by the addition of the sample to the test system, by reference to a standard curve.
A process for preparing an immunoassay for quantitatively assaying a biological material for an immunological substance by means of immunochemical binding of immune complexes to insolubilized non-immunospecific factor having binding affinity for said complexes, which are composed of said immunological substance and an immunospecific conjugate which interacts specifically with said immunological substance, the degree of immunochemical binding of said immune complexes to said insolubilized non-immunospecific factor being a function of composition of said immune complexes and representable by an generally bell-shaped binding curve established over a range of compositions of said immune complexes, said range including compositions in which the amount of said immunological substance and the amount of said immunospecific conjugate are in substantial equivalence, in which the amount of said immunological substance is in substantial excess of the amount of said immunospecific conjugate, and in which the amount of said immunospecific conjugate is in substantial excess of the amount of said immunological substance, said process comprising the steps of:
A process for preparing an assay for quantitatively assaying a biological material for a monovalent bindable substance by means of inhibition of binding of formed complexes to non-immunospecific factor having binding affinity for said complexes, which are composed of a multivalent form of said bindable substance and a multivalent binding partner which binds said bindable substance specifically, the degree of binding of said formed complexes to said non-immunospecific factor being a function of composition of said formed complexes and representable by generally bell-shaped binding curve established over a range of compositions of said formed complexes, said range including compositions in which the amount of said multivalent form of said bindable substance and the amount of said multivalent binding partner are in substantial equivalence, in which the amount of said multivalent form of said bindable substance is in substantial excess of the amount of said multivalent binding partner, and in which the amount of said multivalent binding partner is in substantial excess of the amount of said multivalent form of said bindable substance, said process comprising the steps of:
Dependencies are inferred from the claim text.